Objective: Increasing interest in the prodromal stage of schizophrenia over the past decade led us to perform our study to monitor people at high risk for developing a psychosis. We hypothesized that cannabis use or a cannabis use disorder at a younger age relates to high-risk symptoms at a younger age.
A mong all inhabitants of Amsterdam, the Netherlands, 38.1% were said to have ever used cannabis, most of them aged between 16 and 29 years. 1 Despite the seemingly innocent and common use by teenagers and adolescents in Amsterdam, uncertainty persists about its psychological consequences. 2 Cannabis use and its association with schizophrenia has been investigated extensively over the last decade. Cannabis intoxication leads to acute transient psychotic episodes in some people. 3, 4 Cannabis abuse has also been associated with psychotic relapses in patients with early psychoses and exacerbation of pre-existing psychotic symptoms. 5, 6 A study 7 shows that in male schizophrenia patients, the use of cannabis is associated with a much earlier onset of the disorder; male cannabis users were, on average, 6.9 years younger at illness onset than male nonusers.
In a review of 5 studies, Arseneault et al 3 concluded that cannabis use was neither a sufficient nor a necessary cause for psychosis, but a component cause and part of a complex constellation of factors leading to psychosis. Cannabis use conferred an overall 2-fold increase in the relative risk for schizophrenia or schizophreniform disorder later in life. Age was found to have a moderating effect: the earlier the age of onset of cannabis use, the greater the risk for psychotic outcomes. Arsenault et al 3 suggested that, when assuming a causal relation, elimination of cannabis use would reduce the incidence of schizophrenia by about 8% at the population level. This is supported by the conclusions described in a review by Murray et al 8 and a meta-analysis performed by Moore et al. 9 Both studies reported that epidemiologic evidence strongly suggests a relation between cannabis use and schizophrenia. Moore et al 9 found an increased risk of psychotic outcome in people who had ever used cannabis (OR 1.41, 95% CI 1.20 to 1.65; heterogeneity P = 0.28, I 2 = 19.2%). They reported greater risk in people who used cannabis most frequently (OR 2.09, 95% CI 1.54 to 2.84, heterogeneity P = 0.11, I 2 = 44.1%).
Interest in the prodromal stage of schizophrenia, the period directly preceding the onset of psychosis, has undergone dramatic increase over the past decade. The prodromal stage can be defined as the stage of schizophrenia that begins with the first changes in behaviour and lasts until the onset of the first psychotic episode. 12 In this stage, subtle deficits can be identified long before the emergence of florid psychosis. These deficits could serve as predictors of later schizophrenia, providing a possibility for preventive intervention. 10, 11 The prodromal period can be characterized by various mental state features, including nonspecific symptoms such as depressed mood and anxiety as well as subthreshold or attenuated psychotic symptoms. 13 Presence of certain basic symptoms (subjective disturbance of attention, thinking, perception, speech, and motor action) has also been described. 14 In the case of schizophrenia, the prodromal period lasts around 2 years on average 12 and is often associated with psychosocial impairment and disability. 13 One important aspect of the prodrome is that it is a period in which intervention could occur if it could be recognized prospectively. The retrospective term prodromal therefore cannot appropriately be used in prospective investigations. After all, it is only after someone has developed a full-blown psychosis one can say with certainty that the symptoms were prodromal. Instead of putatively prodromal, the subjects are referred to as UHR.
Cannabis has cognitive effects, such as subtle impairment of memory or attention and impairment of the organization and integration of complex information. 6 Large doses of tetrahydrocannabinol (one of the effective components of cannabis) produce confusion, amnesia, delusions, hallucinations, anxiety, and agitation. Some of these symptoms resemble cognitive dysfunction and attenuated psychotic symptoms in patients with an increased risk for developing psychosis.
A review by Johns 4 describes several psychiatric effects of cannabis. Cannabis use elicits psychological responses such as panic attacks, anxiety, or depression and it can produce a range of short-lived symptoms, such as depersonalization, derealization, and paranoid ideas. Johns also stated that cannabis use can lead to disorientation, impaired memory, confusion, and disordered thinking with labile affect and hallucinations. An Australian cohort study 15 found that daily cannabis use in young women was associated with an increase in the odds of reporting a state of depression and anxiety. A German study 16 found that the most important acute adverse effects caused by cannabis use are anxiety and panic attacks. They reported effects on psyche and perception, such as anxiety, depersonalization, hallucination, and aggravation of psychotic states. They also reported several effects on cognition, such as fragmented thinking and disturbed memory. Again these symptoms coincide with symptoms described in patients with an increased risk for developing psychosis.
The above-mentioned results led us to select 9 symptoms that were reported in the UHR phase and reported to be owing to cannabis use. These symptoms were anxiety, depressed mood, derealization, depersonalization, hallucinations (in any modality), persecutory ideas, impairment of memory, increased distractibility and (or) disturbance of attention, and weakness of focused thinking. In our study, we investigated the relation between the onset of cannabis use or a cannabis use disorder and the onset of these high-risk symptoms. We made a distinction between patients using cannabis and patients with a cannabis use disorder because of its severity and because we assumed a disorder has more impact on everyday life and therefore may have more effect on symptoms. We hypothesized that cannabis use or a cannabis use disorder at a younger age relates to high-risk symptoms at a younger age.
Method
Our study took place at the Amsterdam site of the Dutch Prediction of Psychosis Study. This study is a naturalistic study with its major focus on the course of UHR symptomatology.
Subjects
Inclusion criteria consisted of subjects aged 12 to 35 years with no previous psychotic episode for more than 1 week, as assessed with the SCID-I, section B and C. 17 In addition, each subject had to fall into one or more of the following groups:
Familial Risk or Schizotypal Personality Disorder in the Identified Patient Plus Reduced Functioning. This group included people with a DSM-IV schizotypal personality disorder or a first-degree relative with a history of any DSM-IV psychotic disorder and a change in mental state or functioning in the person leading to a reduction of 30% or more on the GAF. A best estimate derived from an independent interview with the subject and a close relative, mostly one of the parents, defines the initial baseline of functioning.
Attenuated Psychotic Symptoms. This group included the presence of at least one of the UHR symptoms as assessed with the SIPS. 18 The SIPS is a comprehensive diagnostic tool designed specifically for the assessment of the whole spectrum of prodromal signs and symptoms. The scale is composed of 19 items (5 positive, 6 negative, 4 disorganization, and 4 general symptoms) each of which is given a score of 0 to 6 according to defined criteria. A score between 3 and 5 on the positive symptoms indicates attenuated psychotic symptoms, and a score of 6 indicates a psychotic state. These symptoms should occur at least several times a week and should have been present for at least 1 week.
Brief, Limited, or Intermittent Psychotic Symptoms. This group included a score of 6 on one of the positive items of the SIPS, with duration of less than 1 week and spontaneous remission.
Basic Symptoms. This group included at least 2 self-perceived deficiencies of cognition or perception: basic symptoms assessed with the BSABS-P. 19 The BSABS-P contains 17 selected self-perceived disturbances in cognition and perception that were found to be predictive for a transition to psychosis over a 10-year period. Each basic symptom is given a score of 0 to 6 according to frequency of occurrence. A score of 3 or more on at least 2 of the first 9 items also indicates an UHR state and makes the subject eligible for the study.
Exclusion criteria consisted of an IQ below 85 and symptoms owing to an organic etiological factor or solely related to drug use. Subjects who used cannabis were asked if they had a period of symptoms in which they did not use cannabis and, if not, they were asked to stop using for 2 weeks to see if symptoms continued. Subjects who used hard drugs (for example, cocaine; heroin; 3,4-methyleendioxymethamfetamine; speed; and magic mushrooms) were excluded.
The investigation was carried out in accordance with the latest version of the Declaration of Helsinki. The study design was approved by the Medical Ethical Committee of the Academic Medical Center. Informed consent of all participants was obtained after the nature of the procedures had been fully explained.
Instruments
Cannabis Assessment. The CIDI, section L, was used to collect data on cannabis use in the UHR group. The CIDI is a comprehensive, fully standardized, instrument for assessment of mental disorders according to the definitions and criteria of ICD-10 and DSM-IV. CIDI data show cannabis use, cannabis abuse, and cannabis dependence. Cannabis abuse (305.20) and cannabis dependence (304.30) are DSM-IV classified with ICD-9-Clinical Modification codes. Good reliability and validity of the CIDI have been reported. 20 The CIDI question regarding cannabis use "Have you ever used cannabis more than 5 times to get high, to relax, to feel better, more active, or more alert?" was used to assess lifetime cannabis use. If the answer was positive, participants were considered cannabis users and age of first frequent use was asked.
Cannabis use disorders, that is, cannabis abuse or cannabis dependence, were assessed according to DSM-IV criteria.
Onset of High-Risk Symptoms. With the IRAOS, we assessed early signs and prodromal symptoms of schizophrenia. The instrument assesses time of first occurrence, presence, and temporal course of symptoms with sufficient reliability. 21 In our study, we used the assessment of time of first occurrence. IRAOS allows a detailed and valid qualitative description of the onset and early course of the disease including prodromi, specific, and nonspecific symptoms. 
Statistical Analyses
Data were analyzed with Statistical Package for the Social Sciences 14.0.0 (SPSS Inc, Surrey, GB). The 9 symptoms selected from the IRAOS were also converted into a cluster. If more than one symptom was reported present in the cluster, with different ages at onset, the earliest age of onset was used in the analyses. Thus age of onset in the cluster represents age of onset of the first symptom present of the 9 selected symptoms. For our main hypothesis we used the correlation coefficient Spearman's rank correlation (rho) to test nonparametric correlations. We applied a correction for multiple comparisons. Correlations with a P < 0.02 were considered significant. We studied the cannabis-using group and the group with a cannabis use disorder separately. We investigated the chronology of onset of symptoms and onset of cannabis use within the cannabis-using UHR group. We also looked at differences in reported IRAOS symptoms and in age of onset of symptoms between the cannabis-using group and the noncannabisusing group of UHR participants. For this analysis we used a one-sample Student t test with a test value of zero to test significance of the mean differences in years between the onset of the symptom and the onset of cannabis use.
Results

General Characteristics
From the 285 adolescents referred to our hospital at the time of our study, 74 met the inclusion criteria of UHR and signed informed consent. Two participants were lost owing to early transition to psychosis and 5 participants were not assessed with all questionnaires. Therefore, 68 participants were included for analysis. Among the 68 participants, 69.1% (n = 47) were male and 30.9% (n = 21) were female. The mean age of the participants was 19.0 years (range 12 to 29, SD 3.9). Mean current GAF score was 50 (range 29 to 75, SD 11.1). Among the 68 participants, 94.1% (n = 64) belonged to the group of attenuated psychotic symptoms; 69.1% (n = 47) belonged to the group of basic symptoms; 16.2% (n = 11) belonged to the brief, limited, or intermittent psychotic symptoms group; and 13.2% (n = 9) belonged to the group of familial risk or schizotypal personality disorder and reduced functioning. Thus most patients fell into more than one inclusion category.
A division has been made within the UHR group into cannabis and noncannabis users. Among the 68 participants, 35 (51.5%) had used cannabis more than 5 times in their life. The mean age of onset of cannabis use was 16.8 years (range 13 to 26, SD 3.1) and of the cannabis users 71.4% were male. Among the 68 participants, 22 (32.4%) were diagnosed with a cannabis use disorder. The mean age of onset of cannabis dependence or abuse was 16.7 years (range 14 to 26, SD 3.2) and 81.8% were male. Thirty-five UHR cannabis users were included, of whom 15 participants were using recently. Among the 15 participants, 9 were using frequently (for example, used almost every day), 2 participants used 3 or 4 times a week, 3 participants used 1 to 2 days a week, and 1 participant used 1 to 3 days a month at the time of inclusion. The rest of the cannabis users (n = 20) in the UHR group had used cannabis in the past. The time of last consumption use varied from 2 weeks to more than 1 year ago. Fifity-five percent had used almost every day, 10% used 3 or 4 times a week, 30% used 1 to 2 days a week, and 5% used 1 to 3 days a month.
No significant differences were found between the cannabisand noncannabis-using UHR group. We looked at the number of reported IRAOS symptoms (for both groups, a mean of 3.8) during the whole period and at age at onset of the selected IRAOS symptoms (mean age 14.5 for cannabis users, compared with 14.6 for noncannabis users).
Transition Rate
Seventeen (25%) of the 68 included participants made the transition to psychosis. The mean interval between inclusion and transition of this group was 13.9 months (range 2.5 to 37.0, SD 9.2). The 17 participants were diagnosed with schizophrenia (n = 11), schizophreniform disorder (n = 3), schizoaffective disorder (n = 2), and brief psychotic disorder. Among the 17 participants who made the transition to psychosis, only 5 used cannabis and 3 of them stopped using cannabis before intake.
Age of Onset of Symptoms and Cannabis Use
Age of onset of the high-risk symptoms assessed by the IRAOS was correlated with age of onset of cannabis use ( Table 2) . A younger age of onset of cannabis use was related to younger age of onset of the following symptoms: anxiety, depressed mood, hallucinations, derealization, and persecutory ideas. The cluster of all symptoms was also related to younger age of onset of cannabis use. Table 3 lists correlations between age of onset of symptoms and age of onset of cannabis abuse or dependence. A younger age of onset of cannabis abuse or dependence was correlated to a younger age of onset of the following symptoms: anxiety, hallucinations, persecutory ideas, impairment of memory, and derealization. The cluster of symptoms also was related to age of onset of cannabis abuse or dependence. Age of onset of the symptom depersonalization also was related to age of onset of cannabis abuse or dependence but only 3 participants reported this symptom.
Age of Onset Symptoms and Cannabis Abuse or Dependence
Symptom Chronology
The symptoms reported as first symptom present by most participants were anxiety (reported by 42.9%) and depression (reported by 45.7 %). The symptoms of anxiety, increased distractibility, weakness of focused thinking, and the cluster of symptoms seem to precede cannabis use, with an onset of 2.31 years to 1.19 years before cannabis use. However, the symptoms of increased distractibility and weakness of focused thinking did not show a significant correlation with cannabis use. The symptoms of derealization, depersonalization, hallucinations, and persecutory ideas mostly appeared after participants started using cannabis, with a mean onset of 0.41 years to 1.65 years after cannabis use.
The onset of the symptoms of depression and impairment of memory seemed to coincide with the onset of cannabis use. The mean difference in years of age of onset of cannabis use and age of onset of the cluster of symptoms was significant (t = 2.89, df = 34, P = 0.007).
Discussion
The main finding of our study was that a younger age of onset of cannabis use was related to a younger age of onset of the symptoms: anxiety, depressed mood, derealization, hallucinations, and persecutory ideas. A younger age of onset of cannabis use was also related to a younger age of onset of the cluster of abovementioned high-risk symptoms. A younger age of onset of cannabis use disorder, that is cannabis abuse or dependence, was related to a younger age at onset of the symptoms: anxiety, derealization, hallucinations, persecutory ideas, impairment of memory, and the cluster of symptoms. Further, we found that this population at UHR for developing psychosis started using cannabis at an early age, with a mean age of 17 years (median 16 years, range 13 to 26) and consumed more cannabis (51.5%) than adolescents in Amsterdam (38.1%, with a mean age of 19.9) and the Netherlands (17.0%) according to an epidemiologic study of cannabis use. 1 Most of the UHR group (69%) was male. This result is in concordance with the finding that schizophrenia probably is more frequent in males 22 and because onset of schizophrenia in males is 3 to 4 years earlier than in females. 23 In a review, 24 3 different hypotheses about the relation between cannabis use and psychosis are evaluated: cannabis use causes a psychotic disorder that would not have occurred in the absence of cannabis use, cannabis use may precipitate schizophrenia or exacerbate its symptoms, and that cannabis use may exacerbate the symptoms of psychosis. The authors report limited support for the first hypothesis and reasonable support for the second and third hypothesis. Our study also supports the relation between cannabis use and the onset of (subclinical) psychotic symptoms in people with a vulnerability to develop (subclinical) psychotic symptoms.
In our UHR group, 25% of the patients made a transition to psychosis. However, all participants reported disturbing subclinical psychotic symptoms that induced them to seek help. In addition, they already showed poor functioning as assessed with the GAF scale. Thus, even if patients never develop a psychotic episode, the high-risk symptoms are already related to suffering and poor functioning.
We investigated the relation in the past of age of onset of symptoms with age of onset of cannabis use. Most symptoms develop a significant amount of time before help-seeking behaviour. Among the 35 cannabis users, 20 had stopped using cannabis at time of intake. Although these participants stopped using before intake, cannabis use could have influenced the start of the symptoms in the past. Numerous patients reported that they stopped using cannabis after developing symptoms because of their experience that cannabis worsens at least certain symptoms.
In the cannabis using UHR group, age of onset of cannabis use is correlated to age of onset of high-risk symptoms. Thus patients who start using cannabis at a young age develop high-risk symptoms at a young age and patients who start using cannabis at a later age develop high-risk symptoms at a later age. Our result of an absence of a significant difference between the cannabis and noncannabis group in mean age of onset of the symptoms is not contradictory with our correlational finding. If patients start using at an older age, the mean age of onset of symptoms in the cannabis group increases. In the noncannabis-using UHR group there may be other factors influencing the onset of symptoms. Evidently, cannabis is not the only risk factor for developing psychosis.
The relation between cannabis use and high-risk symptoms has 2 possible implications. First, cannabis use and psychotic symptoms could share a common underlying vulnerability. Second, it could imply a causal relation. If there is a causal relation, what comes first? Or is there possibly a bidirectional causal relation? A 14-year follow-up study done in the Netherlands found that cannabis use, in people who did not have psychotic symptoms, predicted future psychotic symptoms. 25 They also found, that psychotic symptoms in people who had never used cannabis before predicted future cannabis use. Our results show that age of onset of the first symptoms precedes age of onset of cannabis use in our UHR group. It has been reported in previous case-control studies that symptoms such as anxiety and depression are reported less by schizophrenia patients who use cannabis. 26 This result could support the self-medication theory. Cornblatt et al 10, 11 suggested that anxiety and depression are the first symptoms of the UHR phase.
Further, it has been reported that positive symptoms such as hallucinations and delusions are more prominent in cannabisabusing patients with schizophrenia. 27, 28 It could be hypothesized that patients with high-risk symptoms start using cannabis to reduce anxiety, being one of the first symptoms present, and by smoking cannabis they provoke positive symptoms.
We did not find a significant difference in the transition rate between the cannabis-using and nonusing group. Our study reports on a relation in the past between the start of cannabis use and the start of symptoms. Numerous patients had stopped using cannabis before intake. Some patients in our study stopped using cannabis after developing symptoms because of their experience that cannabis worsens at least certain symptoms.
There are limitations to our study. First, it is clear that more definitive conclusions require larger samples. Second, our study was limited by the retrospective nature of the information regarding onset of cannabis use and high-risk symptoms. The answers depended on what the participant remembered of the time symptoms and cannabis use started. It is possible that retrospective reports are not reliable, although this has been contradicted by previous research. [29] [30] [31] Johnson and Mott 30 reported that, of all drugs, questions regarding first use of cannabis were most reliable. Another limitation of our study could be the validity of the information obtained with the IRAOS. Participants' answers regarding the presence of prodromal symptoms were taken at face value. However, the thorough interview necessary to complete the IRAOS also leads to more detailed and sophisticated information than the standard psychiatric interview. 21 In further studies, it would be useful to study larger samples of people with an UHR for developing psychosis. Also it would be interesting to investigate the underlying psychopathology of the relation between age at onset of cannabis use and age of onset of high-risk symptoms.
Implications
Our results add to a growing body of evidence suggesting that regular cannabis use is related to the onset of (subclinical) psychotic symptoms in subjects with a vulnerability to develop psychosis. A clear statement should be made to the government policy-makers that cannabis use has serious side effects. The results of our study show a relation between cannabis use and the UHR phase. This is an important finding because patients in the prodromal phase of schizophrenia already show poor functioning, even before the onset of first psychosis. Prevention of cannabis use could possibly prevent or delay the UHR state and lead to a better outcome.
Résumé: L'âge où débute l'utilisation du cannabis est associé à l'âge où apparaissent les symptômes associés à un risque élevé de la psychose
Objectif : L'intérêt grandissant pour la phase prodromique de la schizophrénie des dix dernières années nous a poussés à entreprendre notre étude pour surveiller les personnes à risque élevé de développer une psychose. Nous avons émis l'hypothèse que l'utilisation du cannabis ou un trouble de l'utilisation du cannabis à un jeune âge est relié à des symptômes associés à un risque élevé de psychose à un jeune âge.
Méthode : Les personnes adressées à l'Academic Medical Centre d'Amsterdam, aux Pays-Bas, ayant un risque ultra-élevé de psychose ont été interviewées à l'aide de l'entrevue diagnostique composite internationale pour évaluer leur consommation de cannabis. L'entrevue d'évaluation rétrospective du début de la schizophrénie a été utilisée pour recueillir les données sur l'âge du début des symptômes associés à un risque élevé de psychose ou prodromiques. Neuf symptômes associés à un risque élevé de psychose ont été sélectionnés et regroupés en raison de leur relation connue avec l'utilisation du cannabis.
Résultats : Parmi les 68 participants inclus, 35 avaient utilisé du cannabis (51,5 %), et 15 d'entre eux en avaient utilisé récemment. Vingt-deux participants avaient abusé du cannabis ou avaient été dépendants du cannabis (32,4 %) dans le passé. Le jeune âge au début de l'utilisation du cannabis était relié au jeune âge à l'apparition du groupe de symptômes (rho = 0,48; P = 0,003) et aussi à 6 symptômes individuellement (rho = 0,47 à 0,90; P < 0,001 à 0,04). Le jeune âge au début du trouble de l'utilisation du cannabis était relié au jeune âge à l'apparition du groupe de symptômes (rho = 0,67; P = 0,001) et aussi à 6 symptômes individuellement (rho = 0,50 à 0,93; P = 0,007 à 0,03).
Conclusion : L'utilisation du cannabis ou un trouble de l'utilisation du cannabis à un jeune âge dans un groupe à risque ultra-élevé de transition à la psychose est relié à l'apparition de symptômes à risque élevé de psychose à un jeune âge.
